Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
89943-82-8
Molecular formula
C14H12ClNO2
Molecular weight
261.7 g/mol
Drug class
Low-ceiling diuretic and antihypertensive agent (ATC C03BX03)
Mechanism of action
Produces salidiuretic activity through an active sulfoconjugated metabolite that inhibits a sodium-dependent chloride/bicarbonate exchanger in the distal convoluted tubule. Vasodilator effects are complex and may involve prostaglandin synthesis, cyclic-GMP phosphodiesterase inhibition, calcium-channel effects and potassium-channel opening; the relative clinical contributions are not fully established.
Indications / reported uses
Treatment of arterial hypertension in countries where cicletanine is authorised; antihypertensive use is supported by historical clinical and pharmacological literature, while current market availability is limited
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cicletanine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cicletanine Permitted Daily Exposure (PDE) report (the Cicletanine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cicletanine Occupational Exposure Limit (OEL) report (the Cicletanine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.